No black box warning on record for Vabrinty

As of the latest FDA labeling reviewed, Vabrinty (LEUPROLIDE ACETATE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Vabrinty medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Tumor Flare: Transient increase in serum levels of testosterone during treatment may result in worsening of symptoms or onset of new signs and symptoms during the first few weeks of treatment, including bone pain, neuropathy, hematuria, bladder outlet obstruction, ureteral obstruction, or spinal cord compression. Monitor patients at risk closely and manage as appropriate

No black box warning on record for Vabrinty

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Tumor Flare: Transient increase in serum levels of testosterone during treatment may result in worsening of symptoms or onset of new signs and symptoms during the first few weeks of treatment, including bone pain, neuropathy, hematuria, bladder outlet obstruction, ureteral obstruction, or spinal cord compression. Monitor patients at risk closely and manage as appropriate

Vabrinty Black Box Warning

No black box warning on record for Vabrinty

Other warnings & precautions

Vabrinty Black Box Warning

No black box warning on record for Vabrinty

Other warnings & precautions